ING Groep NV grew its holdings in Incyte Co. (NASDAQ:INCY) by 158.5% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,156 shares of the biopharmaceutical company’s stock after purchasing an additional 8,067 shares during the quarter. ING Groep NV’s holdings in Incyte were worth $909,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Shikiar Asset Management Inc. raised its holdings in shares of Incyte by 534.2% in the 2nd quarter. Shikiar Asset Management Inc. now owns 113,200 shares of the biopharmaceutical company’s stock valued at $7,584,000 after purchasing an additional 95,350 shares in the last quarter. Verition Fund Management LLC raised its holdings in shares of Incyte by 247.4% in the 2nd quarter. Verition Fund Management LLC now owns 20,377 shares of the biopharmaceutical company’s stock valued at $1,365,000 after purchasing an additional 14,511 shares in the last quarter. Baird Financial Group Inc. raised its holdings in shares of Incyte by 93.3% in the 2nd quarter. Baird Financial Group Inc. now owns 57,759 shares of the biopharmaceutical company’s stock valued at $3,870,000 after purchasing an additional 27,886 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Incyte by 75.4% in the 3rd quarter. Nisa Investment Advisors LLC now owns 37,382 shares of the biopharmaceutical company’s stock valued at $2,582,000 after purchasing an additional 16,070 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Incyte by 80.8% in the 3rd quarter. First Trust Advisors LP now owns 1,546,098 shares of the biopharmaceutical company’s stock valued at $106,804,000 after purchasing an additional 691,111 shares in the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.

INCY has been the subject of several recent research reports. Zacks Investment Research lowered shares of Incyte from a “buy” rating to a “hold” rating in a report on Monday, July 23rd. BidaskClub lowered shares of Incyte from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Raymond James restated a “buy” rating on shares of Incyte in a report on Friday, July 27th. Cowen restated a “buy” rating on shares of Incyte in a report on Tuesday, July 31st. Finally, Oppenheimer set a $70.00 price target on shares of Incyte and gave the company a “hold” rating in a report on Tuesday, July 31st. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and thirteen have given a buy rating to the company. Incyte currently has an average rating of “Hold” and a consensus target price of $94.48.

NASDAQ INCY opened at $66.51 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.01. The company has a market cap of $14.15 billion, a P/E ratio of 391.23 and a beta of 1.12. Incyte Co. has a 52 week low of $58.33 and a 52 week high of $107.10.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.38 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.02). Incyte had a positive return on equity of 2.23% and a negative net margin of 6.07%. The firm had revenue of $449.68 million for the quarter, compared to the consensus estimate of $448.34 million. During the same quarter last year, the firm earned $0.19 EPS. The company’s revenue was up 17.9% compared to the same quarter last year. Research analysts forecast that Incyte Co. will post 0.43 earnings per share for the current fiscal year.

In related news, Director Jean Jacques Bienaime purchased 1,000 shares of the business’s stock in a transaction on Thursday, November 8th. The shares were acquired at an average price of $68.77 per share, for a total transaction of $68,770.00. Following the purchase, the director now owns 6,168 shares of the company’s stock, valued at approximately $424,173.36. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paula J. Swain sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 21st. The shares were sold at an average price of $70.00, for a total transaction of $700,000.00. Following the transaction, the executive vice president now owns 42,324 shares in the company, valued at approximately $2,962,680. The disclosure for this sale can be found here. Insiders have sold a total of 31,000 shares of company stock worth $2,202,100 in the last 90 days. 17.20% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.dailypolitical.com/2018/11/19/ing-groep-nv-grows-holdings-in-incyte-co-incy.html.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Featured Article: What is intrinsic value?

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.